Price to Operating Profit (P/OP)
since 2005
Calculation
Celgene Corp., P/OP, long-term trends, calculation
| P/OP | = | Share price1, 2, 3 | ÷ | Operating profit per share1 | Operating profit per share1 | = | Operating income (loss)1 (in millions) |
÷ | No. shares of common stock outstanding2 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 26, 2019 | 12.13 | = | 89.71 | ÷ | 7.39 | 7.39 | = | 5,191 | ÷ | 702,164,345 | |
| Feb 7, 2018 | 15.21 | = | 95.16 | ÷ | 6.26 | 6.26 | = | 4,707 | ÷ | 752,175,608 | |
| Feb 10, 2017 | 28.40 | = | 115.61 | ÷ | 4.07 | 4.07 | = | 3,167 | ÷ | 777,966,471 | |
| Feb 11, 2016 | 34.53 | = | 99.59 | ÷ | 2.88 | 2.88 | = | 2,255 | ÷ | 781,664,535 | |
| Feb 20, 2015 | 39.23 | = | 123.43 | ÷ | 3.15 | 3.15 | = | 2,519 | ÷ | 800,590,656 | |
| Feb 13, 2014 | 36.98 | = | 82.37 | ÷ | 2.23 | 2.23 | = | 1,809 | ÷ | 812,040,158 | |
| Feb 15, 2013 | 23.68 | = | 49.39 | ÷ | 2.09 | 2.09 | = | 1,746 | ÷ | 837,488,894 | |
| Feb 22, 2012 | 22.70 | = | 37.32 | ÷ | 1.64 | 1.64 | = | 1,443 | ÷ | 877,620,608 | |
| Mar 1, 2011 | 24.91 | = | 26.51 | ÷ | 1.06 | 1.06 | = | 990 | ÷ | 929,797,930 | |
| Feb 18, 2010 | 32.72 | = | 29.95 | ÷ | 0.92 | 0.92 | = | 842 | ÷ | 919,461,836 | |
| Feb 17, 2009 | — | = | 25.94 | ÷ | -1.59 | -1.59 | = | -1,464 | ÷ | 918,926,334 | |
| Feb 20, 2008 | 52.12 | = | 27.44 | ÷ | 0.53 | 0.53 | = | 425 | ÷ | 807,518,156 | |
| Feb 27, 2007 | 114.94 | = | 26.59 | ÷ | 0.23 | 0.23 | = | 175 | ÷ | 755,105,544 | |
| Mar 15, 2006 | 169.22 | = | 20.50 | ÷ | 0.12 | 0.12 | = | 84 | ÷ | 689,939,580 |
Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
1 US$
2 Data adjusted for splits and stock dividends.
3 Closing price as at the filing date of Celgene Corp. Annual Report.
Comparison to Competitors
Celgene Corp., P/OP, long-term trends, comparison to competitors
| Celgene Corp. | AbbVie Inc. | Amgen Inc. | Danaher Corp. | Gilead Sciences Inc. | Regeneron Pharmaceuticals Inc. | Thermo Fisher Scientific Inc. | Vertex Pharmaceuticals Inc. | |
|---|---|---|---|---|---|---|---|---|
| Feb 26, 2019 | 12.13 | 18.35 | 11.46 | 23.18 | 10.15 | 17.53 | 27.33 | 74.57 |
| Feb 7, 2018 | 15.21 | 19.63 | 12.71 | 22.48 | 7.45 | 16.71 | 28.24 | 331.55 |
| Feb 10, 2017 | 28.40 | 10.49 | 12.64 | 21.37 | 5.23 | 28.70 | 25.13 | 2,143.58 |
| Feb 11, 2016 | 34.53 | 11.61 | 13.07 | 17.27 | 5.50 | 30.74 | 22.15 | — |
| Feb 20, 2015 | 39.23 | 28.64 | 19.13 | 17.94 | 10.19 | 49.17 | 20.63 | — |
| Feb 13, 2014 | 36.98 | 14.31 | 16.19 | 16.24 | 28.54 | 42.99 | 30.40 | — |
| Feb 15, 2013 | 23.68 | 10.44 | 12.22 | 13.40 | 16.28 | 35.11 | 17.92 | 4,319.80 |
| Feb 22, 2012 | 22.70 | — | 12.48 | 14.04 | 9.02 | — | 16.64 | 69.48 |
| Mar 1, 2011 | 24.91 | — | 8.79 | 15.14 | 7.82 | — | 17.09 | — |
| Feb 18, 2010 | 32.72 | — | 10.12 | 15.63 | 12.16 | — | 19.04 | — |
| Feb 17, 2009 | — | — | 9.70 | 8.85 | 15.24 | — | 12.33 | — |
| Feb 20, 2008 | 52.12 | — | 12.44 | 13.65 | 18.80 | — | 24.03 | — |
| Feb 27, 2007 | 114.94 | — | 19.54 | 14.52 | — | — | 79.09 | — |
| Mar 15, 2006 | 169.22 | — | 17.96 | 15.18 | 25.01 | — | 21.48 | — |
Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).